Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer.

Trial Profile

Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2016

At a glance

  • Drugs Nivolumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
  • Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms eNERGY; Lena eNERGY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top